Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid

Arthritis and Rheumatism

Volumn 65, Issue 2, 2013, Pages 447-456

  Lauwerys, Bernard R ^a   Hachulla, Eric ^b   Spertini, François ^c   Lazaro, Estibaliz ^d   Jorgensen, Christian ^e   Mariette, Xavier ^f   Haelterman, Edwige ^g   Grouard Vogel, Géraldine ^h   Fanget, Bernard ^h   Dhellin, Olivier ^h   Vandepapelière, Pierre ^h   Houssiau, Frédéric A ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e LAPEYRONIE HOSPITAL   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g ImmuneHealth   (Belgium)

^h not available   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INTERFERON ALPHA KINOID VACCINE; PLACEBO; RECOMBINANT INTERFERON; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; INJECTION SITE ULCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSGENIC MOUSE; VOMITING;

EID: 84873870755     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37785     Document Type: Article

References (19)

1. Tsokos GC,. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110-21.
2. Dorner T, Giesecke C, Lipsky PE,. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther 2011; 13: 243.
3. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J,. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 2001; 294: 1540-3.
4. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610-5.
5. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-23.
6. Yao Y, Higgs BW, Morehouse C, de Los Reyes M, Trigona W, Brohawn P, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-α monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics 2009; 17: 374312.
7. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2951-62.
8. Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011; 70: 1905-13.
9. Bizzini B, Drouet B, Zagury D, Abitbol M, Burny A, Boissier MC,. Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer. Immunotherapy 2010; 2: 347-65.
10. Zagury D, Le Buanec H, Mathian A, Larcier P, Burnett R, Amoura Z, et al. IFNα kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci U S A 2009; 106: 5294-9.
11. Mathian A, Amoura Z, Adam E, Colaone F, Hoekman MF, Dhellin O, et al. Active immunisation of human interferon-α transgenic mice with a human interferon α kinoid induces antibodies that neutralise interferon-α in sera from patients with systemic lupus erythematosus. Ann Rheum Dis 2011; 70: 1138-43.
12. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, et al. Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-α monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1785-96.
13. Committee for Medicinal Products for Human Use. Guideline on clinical evaluation of new vaccines (EMEA/CHMP/VWP/164653/2005). London: European Medicines Agency. URL: http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003870.pdf.
14. European Medicines Agency. ICH Topic E 6 (R1) Guideline for good clinical practice. London: European Medicines Agency.
15. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
16. Gladman DD, Ibanez D, Urowitz MB,. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002; 29: 288-91.
17. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 902-6.
18. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-64.
19. Morimoto AM, Flesher DT, Yang J, Wolslegel K, Wang X, Brady A, et al. Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 2407-15.